Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 9/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 9/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27186380 | 1.00 | KRAS (0.34) | KRASSOS1ROCK2ROCK1KMT2A | |
| SCHEMBL27186105 | 0.85 | KRAS (0.36) | KRASSOS1ROCK2ROCK1KMT2A | |
| SCHEMBL27186109 | 0.85 | KRAS (0.36) | KRASSOS1ROCK2ROCK1KMT2A | |
| SCHEMBL27186172 | 0.83 | SOS1 (0.38) | KRASSOS1ROCK2ROCK1KMT2A | |
| SCHEMBL27186170 | 0.83 | SOS1 (0.38) | KRASSOS1ROCK2ROCK1KMT2A | |
| SCHEMBL27186124 | 0.82 | KRAS (0.35) | KRASSOS1ROCK2ROCK1KMT2A | |
| SCHEMBL27186119 | 0.82 | KRAS (0.35) | KRASSOS1ROCK2ROCK1KMT2A | |
| SCHEMBL27187226 | 0.80 | SOS1 (0.34) | KRASSOS1ROCK2ROCK1KMT2A | |
| SCHEMBL27187229 | 0.80 | SOS1 (0.34) | KRASSOS1ROCK2ROCK1KMT2A | |
| SCHEMBL27187006 | 0.80 | KRAS (0.35) | KRASSOS1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| CN-117651701-A | Novel substituted bicyclic aza heterocycles as SOS1 inhibitors | 唯久生物技术(苏州)有限公司 | 2024-03-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | SOS1, SOS2, KSR1 | KRAS 10/4885SOS1 1/4885ROCK2 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.